Glucotrack, Inc.
GCTKNasdaq
$0.49
↓ -1.6%Jul 17 close · end-of-day
Price
1Y↓ -90.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$805,958.98
Enterprise Value
-$3.1M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$16.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
1984.6%
ROIC
—
Debt / Equity
—
Net Cash
$3.9M
Return 1Y
-91.7%
Company profile
GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel. It develops non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics.
- CEO
- Paul V. Goode
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 5
- Headquarters
- New Jersey
- Website
- glucotrack.com
Earnings
GCTK Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS$2.65↓ -93.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$3.1M | -$4.0M | -$4.4M | -$7.1M | -$14.5M | -$16.1M |
| Net income | -$2.7M | -$4.1M | -$4.4M | -$7.1M | -$22.6M | -$19.4M |
| Diluted EPS | $0.19 | $0.26 | $0.29 | $34.18 | $4,106.00 | $31.22 |
| Operating cash flow | -$3.5M | -$3.8M | -$3.7M | -$6.6M | -$12.5M | -$15.2M |
| Free cash flow | -$3.6M | -$3.8M | -$3.7M | — | -$12.6M | -$15.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$4.5M | -$3.3M | -$3.9M | -$3.5M | -$4.8M | -$4.3M | -$3.5M | -$4.2M |
| Net income | -$4.5M | -$5.1M | -$10.1M | -$6.8M | -$4.8M | -$4.2M | -$3.6M | -$4.3M |
| Diluted EPS | $984.00 | $1,092.00 | $2,041.73 | $40.14 | $9.62 | $4.64 | -$23.18 | $2.65 |
| Operating cash flow | -$1.9M | -$4.1M | -$3.5M | -$2.9M | -$3.7M | -$4.6M | -$3.9M | -$4.0M |
| Free cash flow | -$1.9M | -$4.2M | -$3.5M | -$2.9M | -$3.7M | -$4.7M | -$4.0M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 17, 2026
- 3d agoE.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financingfinance.yahoo.com
- 3d agoGlucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiativesfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-07-11 | Balo Andrew K | Award | 3,332 | $0.00 | $0.00 | filing |
| 2025-07-11 | Malave Luis | Award | 1,200 | $0.00 | $0.00 | filing |
| 2025-07-11 | Carter Erin Catherine | Award | 1,000 | $0.00 | $0.00 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.